Moderna RSV-Targeted mRNA Vaccine Candidate Gets Fast Track Tag In US

  • The FDA granted Fast Track designation Moderna Inc's MRNA mRNA-1345, its investigational single-dose mRNA vaccine against the respiratory syncytial virus (RSV) in adults older than 60 years of age.
  • The respiratory syncytial virus is a common respiratory virus that generally causes cold-like symptoms. 
  • The vaccine is currently in Phase 1 study. All four cohorts of younger adults (ages 18-49 years) are fully enrolled. Dosing in the older adult cohort (ages 65-79 years) is ongoing. 
  • Moderna shared the first interim analysis of the Phase 1 study of mRNA-1345, through 1-month post-vaccination, of the younger adult cohorts.
  • Results showed that the vaccine candidate generated a geometric mean rise in neutralizing antibodies relative to the baseline of at least 11-fold.
  • Moderna also intends to evaluate the potential of combinations of mRNA-1345 with its vaccines against other respiratory pathogens in children and separately in older adults. 
  • Price action: MRNA shares are up 1.12% at $350.79 during the market session on the last check Tuesday.
  • Related content: Benzinga's Full FDA Calendar.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareFDAMoversTrading IdeasGeneralBriefsFDA Fast TrackmRNA vaccinesPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!